A new trading day began on Monday, with Pacific Biosciences of California Inc (NASDAQ: PACB) stock price down -7.07% from the previous day of trading, before settling in for the closing price of $1.98. PACB’s price has ranged from $1.16 to $10.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 24.48%. Meanwhile, its annual earnings per share averaged 4.92%. With a float of $259.36 million, this company’s outstanding shares have now reached $267.74 million.
The extent of productivity of a business whose workforce counts for 796 workers is very important to gauge. In terms of profitability, gross margin is 19.6%, operating margin of -166.74%, and the pretax margin is -218.04%.
Pacific Biosciences of California Inc (PACB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 4.83%, while institutional ownership is 84.06%. The most recent insider transaction that took place on Sep 30 ’24, was worth 34,065. In this transaction an insider of this company sold 19,782 shares at a rate of $1.72, taking the stock ownership to the 695,654 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Officer proposed sale 19,782 for $1.72, making the entire transaction worth $34,061.
Pacific Biosciences of California Inc (PACB) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.26 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.76% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Here are Pacific Biosciences of California Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.50, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
The latest stats from [Pacific Biosciences of California Inc, PACB] show that its last 5-days average volume of 7.03 million was inferior to 9.45 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 66.00%. Additionally, its Average True Range was 0.18.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 61.82%, which indicates a significant increase from 57.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 121.06% in the past 14 days, which was higher than the 119.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6694, while its 200-day Moving Average is $2.9435. Now, the first resistance to watch is $1.9467. This is followed by the second major resistance level at $2.0533. The third major resistance level sits at $2.1267. If the price goes on to break the first support level at $1.7667, it is likely to go to the next support level at $1.6933. Assuming the price breaks the second support level, the third support level stands at $1.5867.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
With a market capitalization of 501.46 million, the company has a total of 272,356K Shares Outstanding. Currently, annual sales are 200,520 K while annual income is -306,740 K. The company’s previous quarter sales were 36,010 K while its latest quarter income was -173,320 K.
